Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Galmed's Aramchol misses in Phase IIa for HIV-associated NAFLD

February 16, 2018 7:40 PM UTC

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) said Aramchol arachidyl amino cholanoic acid missed the primary endpoint in the Phase IIa ARRIVE trial to treat HIV-associated lipodystrophy and non-alcoholic fatty liver disease (NAFLD). The company said it has no further development plans for the product in the indication.

On the 50-patient trial's primary endpoint, once-daily 600 mg oral Aramchol did not significantly reduce liver fat content as measured by MRI proton density fat fraction (MRI-PDFF) from baseline to week 12 vs. placebo. Secondary endpoints in the double-blind, U.S. trial include serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. The trial was sponsored by the University of California San Diego...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Galmed Pharmaceuticals Ltd.